Investigational drug · Phase 2
ABBV-295
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Moderate to Severe Psoriasis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "ABBV-295"
First trial start
2026
Aug 4, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABBV-295", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Moderate to Severe Psoriasis
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "ABBV-295" as an intervention, largest first.
- Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07752979 · 360 participants (planned) · Start Aug 4, 2026 · Primary completion Mar 2028
Drug: ABBV-295; Placebo · For: Obesity; Overweight
Sites: Pelham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 64 sites in all
- A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe PsoriasisPivotal-lookingNot yet recruiting
AbbVieAbbVie (ABBV)
NCT07933536 · 105 participants (planned) · Start Dec 3, 2026 · Primary completion Dec 2028
Drug: Risankizumab; ABBV-295 and 1 more · For: Moderate to Severe Psoriasis
- A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With ObesityActive, not recruiting
AbbVieAbbVie (ABBV)
NCT07291232 · 80 participants · Start Nov 19, 2025 · Primary completion Apr 2027
Drug: ABBV-295; Placebo · For: Obesity
Sites: Anaheim, California; Grayslake, Illinois
- A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.Active, not recruiting
AbbVieAbbVie (ABBV)
NCT07514260 · 24 participants · Start Mar 31, 2026 · Primary completion Dec 2026
Drug: ABBV-295; Placebo for ABBV-295 · For: Healthy Volunteer
Sites: Anaheim, California
AbbVieAbbVie (ABBV)
NCT07414784 · 20 participants · Start Feb 11, 2026 · Primary completion Aug 4, 2026
Drug: ABBV-295; Levonorgestrel/Ethinyl Estradiol · For: Healthy Volunteer
Sites: Anaheim, California; Grayslake, Illinois
Newest research
PubMed records naming it or its code names, newest first.
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
Alhazmi A, le Roux CW · Diabetes Obes Metab 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.